Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 17 2021 - 4:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, today announced its participation in
the Piper Sandler 33rd Annual Virtual Healthcare Conference. From
November 22nd to December 2nd, presentations will be available for
registered attendees via the Piper Sandler conference site. Exagen
will be participating in one-on-one meetings on December 1st.
Meetings can be requested exclusively via Piper Sandler.
Ron Rocca, Exagen’s President and Chief Executive Officer, and
Kamal Adawi, Chief Financial Officer, will participate in a virtual
presentation. Interested parties may access the webcast of the
presentation using a link on Exagen’s website at
https://investors.exagen.com/events
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable providers to improve care for patients
through the differential diagnosis, prognosis, and monitoring of
complex autoimmune and autoimmune-related diseases, including
rheumatoid arthritis and lupus. For further information please
visit www.exagen.com
Forward Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on Exagen’s
current beliefs and expectations. The inclusion of forward-looking
statements should not be regarded as a representation by Exagen
that any of its plans will be achieved. Actual results may differ
from those set forth in this press release due to the risks and
uncertainties inherent in Exagen’s business, including, without
limitation: the COVID-19 pandemic may continue to adversely affect
our business, financial condition and results of operations,
including as a result of shutdowns of our facilities and operations
as well as those of our suppliers and courier services, impeding
patient movement and interruptions to healthcare services causing a
decrease in test volumes, disruptions to the supply chain of
material needed for our tests, our sales and commercialization
activities and our ability to receive specimens and perform or
deliver the results from our tests, delays in reimbursement and
coverage decisions from Medicare and third-party payors and in
interactions with regulatory authorities, and delays in ongoing and
planned clinical trials involving our tests; the company’s
commercial success depends upon attaining and maintaining
significant market acceptance of its testing products and promoted
therapeutics among rheumatologists, patients, third-party payors
and others in the medical community; the company’s ability to
successfully execute on its business strategies, including its
strategy of integrating the promotion of its existing and future
proprietary testing products with the promotion of therapeutics;
third party payors not providing coverage and adequate
reimbursement for the company’s testing products or promoted
therapeutics; the company’s ability to obtain and maintain
intellectual property protection for its testing products;
regulatory developments affecting the company’s business; and other
risks described in the company’s prior press releases and the
company’s filings with the Securities and Exchange Commission
(SEC), including under the heading “Risk Factors” in Exagen’s
Annual Report on Form 10-K for the year ended December 31, 2020 and
any subsequent filings with the SEC. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof, and Exagen undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
Investor RelationsExagen Inc.Ryan
Douglasrdouglas@exagen.com760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Aug 2023 to Aug 2024